HUEVMED@EC2703A

Everbright Bio Obtains NMPA Approval for New Drug VELSIPITY® for Ulcerative Colitis

Cloudtop Echos Receives Exclusive Commercialization Authorization for MT1013 in China and Asia Pacific

Merck & Moderna Disclose mRNA Cancer Vaccine Five-Year Clinical Data

Wu Yifang Increases Holdings in CanSino Biologics by 30,000 Shares

Chairman Wu Yifang of CanSino Biologics Purchased 30,000 Shares

CanSino Biologics Shares Plunge Over 20% After Generic Drug Approval

CloverDX Receives FDA Approval and License from Lib Therapeutics

Everbright Neon Announces 2030 Development Strategy

Top Directors and Major Shareholders of CanSino Biologics Increase Their Shares

Everbright BioTech Signs Commercialization and Licensing Agreement with Haisen Biopharma

Everbright Bio displays latest clinical data of Nefecon at APCN 2025

Everbright Bio Launches Global Phase I Trial for EVM14

Everbright Bio Displays Core Product Nafaquan at ASN Kidney Week

Everbright Bio-Medicines Acquires Exclusive License From Visara For Clinical Development

Cloud Top 耀 Secures Exclusive License for VIS-101, Entering Ophthalmology Market

Innovent Biologics Holds Strategic Investor Meeting

Yutong Xinyao's EVM14 Injection Enters First Patient in Global Phase I Clinical Trial

Everbright Biosec Submits IND for EVM14, a Universal Off-the-Shelf Cancer Therapeutic Vaccine

Cloud Top 耀 Announces Progress of Etrasimod for Ulcerative Colitis

Efinity by CanSino Biologics Nominated in Clinical Guidelines for First-Line IgA Nephropathy Therapy

KO YO GROUP

GEOTECH HLDGS

CHINA INFO TECH

REDCO HEALTHY

AGTECH HOLDINGS

CH CITY INFRA

RMH HOLDINGS

MATRIX HOLDINGS

SOFTMEDX

PUTIAN COMM

01952

云顶香港

DBS Research has upgraded the rating of Genting Singapore to "Buy," with a target price of SGD 0.90, believing that capital return plans such as share buybacks or special dividends are expected to enhance valuation and unlock shareholder value. Genting Singapore's stock price rose 3.25% to SGD 0.795. Analysts pointed out that the company has net cash per share exceeding SGD 0.27, and with major shareholders facing liquidity constraints, implementing a fair participation offer may become an effective short-term value release method. Despite having large capital expenditure projects, the company still has the capacity to pay over SGD 1 billion in cash

Zaobao

EVEREST MED

After DBS analysts upgraded their rating, Genting Singapore's stock price rose by over 3% | Lianhe Zaobao

FLYU

NCLH

Star Cruises cancelled a scheduled sailing from Hong Kong due to an unforeseen technical issue, leaving passengers frustrated after long waits. The company offered rescheduling options or full refunds, along with HK$200 dining vouchers and transport cost coverage. Passengers criticized the handling of the situation, describing their experience as being treated like "refugees". Star Cruises has not disclosed details about the technical issue or when it was identified, but remains committed to providing a safe travel experience.

南华早报

Invesco Leisure & ENT ETF

MicroSectors™ Travel 3X Leveraged ETNs

Norwegian Cruise

Angry passengers left high and dry after Star Cruises cancels Hong Kong sailing

159102

516820

159837

159506

159992

516500

588130

159849

159859

512010

588250

516930

Everest Medicines Ltd. has received approval from the National Medical Products Administration (NMPA) in China for VELSIPITY (etrasimod arginine tablets) to treat adults with moderate to severe active ulcerative colitis who have inadequate response, loss of response, or intolerance to conventional therapies or biological agents. The company is preparing for the product launch in China and plans to include it in the national reimbursement list.

Reuters

Huaan Hang Seng Biotech ETF

Ping An CSI Medicine and Medical Device Innovation ETF

E Fund CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

ChinaAMC SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI 300 Health Care ETF

Penghua SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

Everest Medicines erhält Zulassung für VELSIPITY in China

513700

520880

159316

159570

513060

159567

Everest Medicines Limited has secured an exclusive license from Shaanxi Micot Pharmaceutical Technology Co., Ltd. to commercialize MT1013 in Greater China and other Asian markets. MT1013 is a first-in-class dual-targeting receptor agonist polypeptide aimed at treating secondary hyperparathyroidism, with potential expansion into chronic kidney disease-mineral and bone disorder and osteoporosis. This collaboration will enhance Everest Medicines’ nephrology portfolio.

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Penghua CSI HK Connect Health Care Composite ETF

iShares Biotechnology ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

iShares US Pharma

E Fund Hang Seng SCHK Innovative Drug ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Bosera Hang Seng Health Care ETF(QDII)

Yinhua CNI HK Connect Innovative Drugs ETF

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Everest Medicines Secures Exclusive License to Commercialize MT1013 in Greater China and Asia

Everest Medicines Ltd. will hold an extraordinary general meeting on February 22, 2026, as a virtual session. The agenda includes the approval of ongoing connected transactions related to the Commercialization Service Agreement, proposed allocation of shares to a connected person, application for a waiver of certain requirements, and the planned introduction of the 2026 Share Scheme. This information was published via the Issuer Information Service by the Hong Kong Stock Exchange.

Everest Medicines gibt Termin für außerordentliche Hauptversammlung bekannt

Genting Singapore has appointed acting CEO Lim Kok Thay as the Chairman and Director of Resorts World Sentosa, effective February 1. Lim Kok Thay will lead the Resorts World board, responsible for strategic direction and governance oversight. The daily management of Resorts World will be handled by the management team led by Lee Xi Ru

Genting Sing

Genting Group Executive Chairman Lim Kok Thay appointed Chairman of Resorts World Sentosa | Lianhe Zaobao

520690

513120

Everest Medicines Limited has signed a lease agreement through its subsidiary, Everest Medicines Trading (Shanghai) Co., Ltd., with Kang Pu as the lessor. The agreement involves leasing certain premises for a specified term. Mr. Wei Fu, a non-executive director with a material interest in the transaction, abstained from voting on the board resolutions. The company confirmed compliance with the Hong Kong Listing Rules regarding necessary approvals.

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

China Southern Hang Seng Biotech ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Yinhua CSI Research Sector 100 ETF

Everest Medicines Signs Lease Agreement for New Premises

Everest Medicines Ltd. will present a company update at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 7:30 a.m. PT in San Francisco. The management team will also engage in one-on-one meetings during the conference from January 12 to 15, 2026. A live webcast of the presentation will be available on the company's website.

Everest Medicines to Present Company Update at J.P. Morgan Healthcare Conference

HUEVMED@EC2703A(23826.HK)

After DBS analysts upgraded their rating, Genting Singapore's stock price rose by over 3% | Lianhe Zaobao

Angry passengers left high and dry after Star Cruises cancels Hong Kong sailing

Everest Medicines erhält Zulassung für VELSIPITY in China

Everest Medicines Secures Exclusive License to Commercialize MT1013 in Greater China and Asia

Everest Medicines gibt Termin für außerordentliche Hauptversammlung bekannt